Common sequence variants at the haptoglobin gene (HP) have been associated with blood lipid levels. Through wholegenome sequencing of 8,453 Icelanders, we discovered a splice donor founder mutation in HP (NM_001126102.1:c.190 þ 1G > C, minor allele frequency ¼ 0.56%). This mutation occurs on the HP1 allele of the common copy number variant in HP and leads to a loss of function of HP1. It associates with lower levels of haptoglobin (P ¼ 2.1 Â 10 À54 ), higher levels of non-high density lipoprotein cholesterol (b ¼ 0.26 mmol/l, P ¼ 2.6 Â 10 À9 ) and greater risk of coronary artery disease (odds ratio ¼ 1.30, 95% confidence interval: 1.10-1.54, P ¼ 0.0024). Through haplotype analysis and with RNA sequencing, we provide evidence of a causal relationship between one of the two haptoglobin isoforms, namely Hp1, and lower levels of non-HDL cholesterol. Furthermore, we show that the HP1 allele associates with various other quantitative biological traits. † These authors contributed equally to this work.
Introduction
Haptoglobin is an abundant plasma protein whose best characterized function is to capture free hemoglobin and mediate its clearance from the circulation (1, 2) . The two haptoglobin isoforms, Hp1 and Hp2, are related to a common intragenic copy number variant (CNV) in HP (Fig. 1A) . The HP CNV is characterized by a variable number of copies of a 1.7 kilobase (kb) segment encompassing two exons (3) . An individual may carry either one or two copies of this segment on each chromosome: HP1 is the single-copy allele and HP2 is the two-copy allele. The frequency of HP1 is 39.0% in Iceland, similar to other European populations (4) . Recently, Boettger et al. studied the evolutionary origin of the HP CNV and concluded that modern HP1 alleles have been generated through recurring deletions in HP2 (5) . HP CNV genotypes, traditionally inferred using protein gel electrophoresis (1), have been reported to associate with a wide variety of human conditions (4, 6) . The best established association of the HP CNV is with blood cholesterol levels; HP1 has been associated with lower levels of total cholesterol and low-density lipoprotein (LDL) cholesterol, but the mechanism underlying this relationship is not well understood (5, (7) (8) (9) .
In this study, we searched for sequence variants that influence haptoglobin levels in a genome-wide association study of sequence variants identified through large-scale whole-genome sequencing in the Icelandic population. We constructed haploypes and examined their effects on expression of HP transcripts in an RNA sequencing dataset. We then tested for association with blood lipid levels and coronary artery disease in addition to 2,491 other binary and quantitative biological traits in a large population-based sample.
Results

Genome-wide association study of haptoglobin levels
To search for sequence variants influencing serum haptoglobin levels, we analyzed variants detected through wholegenome sequencing of 8,453 Icelanders and imputed into 150,656 chip-typed individuals and their close relatives (10) . Assuming an additive model, we tested 30.5 million SNPs and insertions/deletions (indels) in a genome-wide scan of haptoglobin levels in 13,394 Icelanders (mean ¼ 1.83 g/l, standard deviation (s.d.) ¼ 1.17 g/l). We used class-specific thresholds for genome-wide significance based on functional annotation of the variants: 1.9 Â 10 À6 for high impact variants, 1.1 Â 10 À7 for moderate impact variants and 5.5 Â 10 À10 for low impact variants (Materials and Methods). The HP CNV was genotyped using a method based on read depth in whole-genome sequencing data and imputed and tested for associations (Materials and Methods). We found significant associations at 16q22, in a region encompassing the HP gene. Using stepwise conditional analysis, we identified three distinct association signals at this locus, represented by three variants (Table 1 , Fig. 2 , Supplementary Material, Fig. S1 ). For each variant, the association results are presented with adjustment for the other two variants (b adj and P adj ). The first signal is represented by HP1, that associates with higher levels of haptoglobin (b adj ¼ 0.17 g/l, P adj ¼ 6.5 Â 10
À32
, allele frequency ¼ 39.0%, Table 1 ). The second signal is represented by a novel splice donor mutation in HP (NM_001126102.1:c.190 þ 1G > C) that markedly lowers haptoglobin levels (b adj ¼ À1.47 g/l, P adj ¼ 2.1 Â 10
À54
, allele frequency 0.56%, Table 1 ). This mutation is located at the first base of intron 3 and is only observed on the background of HP1 (D'¼ 1.00, r 2 ¼ 0.0089, Supplementary Material, Table S1 ). The splice donor mutation has neither been reported in large publicly available datasets (Exome Aggregation Consortium database and the UK10K project, URLs) nor was it detected by direct genotyping in 4,955 Dutch samples from the Nijmegen Biomedical Study (11) , indicating that it may be a founder mutation in Iceland (Supplementary Material, Supplementary Note).
The third association signal is represented by a 1-bp deletion located 9 locus, or in other regions of the genome, were significantly associated with haptoglobin levels after adjustment for the HP CNV, the splice donor mutation and rs35283911. We estimated the upper bound for heritability of haptoglobin levels to be 25.8% (95% CI: 13.6, 34.0%), based on 1 705 full sibling pairs, consistent with a previous estimate of 26% (12) . Together, the HP CNV, splice donor mutation and rs35283911[T] explained 3.7% of the phenotypic variance in haptoglobin levels (1.0, 1.8 and 0.9%, respectively) and thus $14% (0.037/0.258) of the heritability.
We observed no sign of recombination between the three biallelic variants that together define four distinct haplotypes (Table 2 , Fig. 1B ). Each haplotype associates with different levels of haptoglobin; the rare haplotype defined by HP1, the splice donor mutation and the major allele of rs35283911 associates with the lowest level, 1.30 g/l below the mean (1.83 g/l) ( Table 2) .
RNA sequencing
To gain insight into the functional impact of the three sequence variants, we investigated their association with expression of HP transcripts using RNA sequencing in whole blood from 1,786 individuals (Materials and Methods). The NCBI Reference Sequence (RefSeq) database contains two transcripts of HP that encode the two haptoglobin isoforms, Hp1 and Hp2. These transcripts differ in length and the number of coding exons: Hp1 is encoded by the short transcript (NM_001126102, 1,301 bp, five exons) and Hp2 is encoded by the long transcript (NM_005143, 1,478 bp, seven exons). All of the three variants associate with expression of HP transcripts (Table 3 , Fig. 3 ). As expected, the two haplotypes containing HP2 associate with higher expression of the long transcript than the haplotypes containing HP1 (P ¼ 9.1 Â 10
À183
, Table 3, Supplementary Material, Table S2 ). In addition, rs35283911[TG] on the background of HP2 associates with even higher expression of the long transcript than the haplotype with HP2 and rs35283911[T] (P ¼ 1.9 Â 10 À69 , Table 3 ).
Carriers of the splice donor mutation had the lowest expression of the short transcript (P ¼ 6.8 Â 10
À105
, Table 3 ). The rare haplotype characterized by the splice donor mutation on the background of HP1 associated with almost complete absence of expression of the short transcript (estimated haplotypic expression as fraction of the sample mean: 0.00; 95% CI: 0.00, 0.14; Figure 1 . Haplotypes at the HP locus associate with expression of the two HP transcripts, levels of haptoglobin and non-HDL cholesterol. (A) A schematic representation of the HP gene. The two alleles of the HP CNV differ in the number of copies of a two-exon segment (grey boxes): HP2 contains two copies and HP1 contains one copy. The splice donor mutation (red star) is only observed on HP1 and causes loss of function of the allele. rs35283911 (not shown) is located 9 kb upstream of HP.
Supplementary Material, Table S2 ). The drastically lower expression of the short transcript and haptoglobin levels with the splice donor mutation is consistent with elimination of the abberant mRNA transcripts through nonsense mediated decay and thus causing a loss of function of HP1.
Associations with blood lipid levels
The HP CNV and the nearby SNP rs2000999 in HPR have been associated with levels of total cholesterol and LDL cholesterol (5, (7) (8) (9) 14) , but the biological mechanism underlying these associations is not well understood. We assessed the association of the three variants described here and the corresponding haplotypes with blood lipid levels in a large population set from Iceland (Materials and Methods).
In our data, two of the three identified variants associate with non-HDL cholesterol (n ¼ 136,262) after adjusting for the two others (Table 1) . Consistent with previous reports, HP1 associates with lower levels of non-HDL cholesterol (b adj ¼ À0.064 mmol/l, P adj ¼ 1.8 Â 10 À19 ). Conversely, the splice donor mutation is associated with higher levels of non-HDL cholesterol (b adj ¼ 0.26, mmol/l, P adj ¼ 2.6 Â 10
À9
). The third variant, rs35283911, does not associate with non-HDL cholesterol levels after adjustment for the other two variants (P adj ¼ 0.089). The HP CNV and splice donor mutation corresponded to the two strongest non-HDL associations at the HP locus and nothing remained locus-wide significant after adjusting for them (Supplementary Material, Fig. S2 ).
The haplotype containing HP1 without the splice donor mutation associates with the lowest levels of non-HDL cholesterol (À0.045 mmol/l relative to the sample mean, 95% CI: À0.055, À0.035 mmol/l; Table 2 ) while the haplotype containing HP1 with the splice donor mutation associates with the highest levels (þ0.18 mmol/l relative to the sample mean, 95% CI: þ0.090, þ0.27 mmol/l; Table 2 ). The effects of the haplotypes on levels of non-HDL cholesterol are inversely correlated with the effects on expression of the short transcript (Fig. 1E ). In contrast, there is no correlation with the effects on expression of the long transcript (Fig. 1F) . These results indicate that HP1, which encodes the short transcript, and thus the resulting protein Hp1, contributes to lower levels of non-HDL cholesterol.
The alleles of the HP CNV are divided into subtypes by nucleotide polymorphisms that cause the protein isoforms to run faster ('F' allele) or slower ('S' allele) on a protein gel (15, 16 
Associations with coronary artery disease
Given that non-HDL cholesterol is a causal risk factor for cardiovascular disease (17), we tested for association with coronary artery disease (CAD) in 25,075 cases and 315,395 controls from Iceland (Table 1) . Consistent with the direction of effect on non-HDL cholesterol, the splice donor mutation associates with greater risk of CAD (adjusted odds ratio [OR adj ] ¼ 1.30; 95% CI: 1.10, 1.54; P adj ¼ 0.0024). However, HP1 does not associate with lower risk of CAD in our data (OR adj ¼ 1.01, 95% CI: 0.98, 1.04) although it associates significantly with lower levels of non-HDL cholesterol (b adj ¼ À0.064 mmol/l, 95% CI: À0.078, À0.050) ( Table  1) . We observed a non-linear relationship between the effects of the HP haplotypes on levels of non-HDL cholesterol and risk of CAD (Fig. 1G) . Associations results for the variants identified in a genome-wide association study of serum haptoglobin levels (n ¼ 13,394) and associations with levels of non-HDL cholesterol (n ¼ 136,262) and coronary artery disease before the age of 76 (n cases ¼ 25,075; n controls ¼ 315,395). Effect estimates are given respect to allele A1 and have been adjusted for the other two variants in the table. Unadjusted effect estimates are shown in Supplementary Material, Table S11 . Equivalence classes for the splice donor mutation and rs35283911 (r 2 > 0.80) are shown in Supplementary Material, Tables S12 and S13, respectively.
Freq. A1, allelic frequency of allele A1; CI, confidence interval.
Homozygotes for the splice donor mutation
We have previously catalogued predicted complete human knockouts in Iceland (18) . For the splice donor mutation, we identified six imputed homozygotes out of 150,656 individuals and confirmed their genotype by Sanger sequencing (Supplementary Material, Table S7 ). Five of them are currently alive and between the ages of 47 and 69, the sixth died at the age of 91. Five had offspring. Unfortunately, no haptoglobin measurements were available for these individuals. Whole gene deletions of the HP gene have been described in East and Southeast Asians (19, 20) . Homozygosity for these deletions is associated with complete absence of serum haptoglobin but is otherwise thought to be clinically silent (19, 20) . Taken together, these data indicate that haptoglobin is not essential for human life.
Associations with other biological traits
To gain further insights into the biological consequences of the HP variants, we screened for associations with 2,491 binary and quantitative traits in Iceland (10) Table 4 ). Given the number of tests perfomed, no other significant associations were found between the HP CNV, splice donor mutation or rs35283911[T] and the 2,491 phenotypes tested for each of the variants (P > 6.7 Â 10 À6 ).
To our knowledge, associations with ESR or levels of LDH have not been reported at the HP locus. The HP CNV explains the previously reported association of rs7186908 with ALP (21) (r 2 ¼ 0.24, D'¼ 0.77) (P adj ¼ 0.010) and remains highly significant after adjustment for rs7186908 (P adj ¼ 7.3 Â 10
À10
). Testing for other markers of inflammation, liver function and tissue damage did not provide evidence of potential biological pathways that might underlie these associations (Supplementary Materials, Tables S8 and S9) .
Given the role of haptoglobin as a scavenger of free hemoglobin, we assessed the relationship between the three identified variants and several erythrocyte traits (Supplementary Material, Table S10 ). We observed a suggestive association between HP1 and lower RBC count (b adj ¼ À0.014 s.d., P adj ¼ 5.7 Â 10 À5 ), consistent with a previous report (22) , while the splice donor mutation showed an effect in the opposite direction (b adj ¼ 0.079 s.d.,
). Similar effect directions were observed for hemoglobin concentration.
Discussion
In this study, we describe a novel splice donor mutation in HP that causes a loss of function of the HP1 allele of the HP CNV, resulting in low serum levels of haptoglobin. We confirm the findings of a recent study that demonstrated an association of HP1 with lower levels of total cholesterol and LDL cholesterol in a sample of 22,288 individuals (5). We show that the loss of function of HP1 associates with higher levels of non-HDL cholesterol and thus provide evidence of a causal link between HP1 and lower levels of non-HDL cholesterol. Our analyses suggest that this relationship is most likely mediated by the smaller of the two haptoglobin isoforms, namely Hp1, which arises from the short gene transcript. Haptoglobin has been shown to interact with apolipoprotein E and to modulate the activity of lecithin:cholesterol acyltransferase (23, 24) , providing a potential link to cholesterol metabolism. It has been speculated that the association of HP1 with lower cholesterol levels may be mediated through greater anti-oxidative effects of Hp1 (25) on apolipoprotein E, thereby promoting clearance of plasma lipids (5) . However, the molecular details of the role of Hp1 in cholesterol metabolism remain to be elucidated.
The loss of function of HP1 conferred by the splice donor mutation is associated with higher risk of CAD. This is consistent with the effect on non-HDL cholesterol, a causal risk factor for cardiovascular disease. Interestingly, however, HP1 does not appear to associate with lower risk of CAD although it associates with lower levels of non-HDL cholesterol. Although the magnitude of the effect of HP1 on non-HDL cholesterol is modest and a small effect on cardiovascular risk cannot be excluded, this finding was somewhat unexpected. Our results suggest that the relationship between HP variants and risk of CAD may not be exclusively related to their effects on non-HDL cholesterol. The HP CNV is highly pleiotropic, associating with multiple biological traits beyond lipids in our data, emphasizing the heterogeneous and complex nature of the locus (Figure 4) .
In summary, through large-scale whole genome-sequencing combined with RNA-sequencing in a richly phenotyped population in Iceland, we provide evidence of a causal role of the (hg38). Red crosses represent -log10P values when adjusted for the HP CNV, splice donor mutation and rs35283911; each remains significant after adjusting for the other two (see Table 1 
Materials and Methods
Icelandic study population
Subjects were enrolled as part of various genetic programs at deCODE Genetics, Reykjavik, Iceland. Personal identifiers of the patients and biological samples were encrypted in accordance with the regulations of the Icelandic Data Protection Authority. All subjects who provided blood samples for DNA analysis gave written informed consent and the study was approved by the National Bioethics Committee of Iceland and the Icelandic Data Protection Authority.
Haptoglobin levels. The genome-wide association scan was performed in 13,394 individuals with available measurements of haptoglobin levels. The measurements were performed for clinical indications and were obtained from two of the largest laboratories in Iceland: Landspitali University Hospital (LUH) in Reykjavik, Iceland and The Icelandic Medical Center (Laeknasetrid) laboratory in Mjodd, Reykjavik, Iceland. Serum haptoglobin concentrations were determined by immunoturbidimetry using Cobas Fara and Roche-Hitachi 912 automatic analyzers and commercially available reagents from Boehringer Mannheim and Roche Diagnostics. A total of 21,163 haptoglobin measurements were obtained. The average age at measurement was 59. The individuals had a median of 1 (range 1-130) and an average of 1.5 haptoglobin measurements. The mean haptoglobin concentration was 1.83 g/l (s.d. ¼ 1.17 g/l). A total of 13,394 genotyped subjects with serum haptoglobin measurements were included in the study, where 8,813 were chip-genotyped with directly imputed genotypes and 4,581 were first and second degree relatives of chip-typed individuals and had their genotyped inferred based on Icelandic genealogical data (10) . Haptoglobin measurements were adjusted for sex, year of birth, age at measurement and measurement site, using the average of multiple measurements for an individual, and then normalized to a standard normal distribution using quantile normalization. Relative to the average risk in the population. . Non-HDL cholesterol was calculated as total cholesterol minus HDL cholesterol. LDL cholesterol was calculated using the Friedewald equation for samples with triglyceride levels <4.00 mmol/l. Lipid levels were adjusted for sex, year of birth, age at measurement, measurement site and lipid lowering medication, using the average of multiple measurements for an individual, and then normalized to a standard normal distribution using quantile normalization; triglyceride levels were quantile normalized to a standard normal distribution before adjustment. The distribution of triglyceride levels is approximately log normal so the effect estimates were presented as percentage change by multiplying the standardized effect with the standard deviation of the log transformed levels and exponentiating.
Coronary artery disease. The coronary artery disease casecontrol sample set consisted of 25,075 cases with age at onset before 76 years of age and 315,395 controls. Cases were defined by: (i) discharge diagnoses according to the International Classification of Diseases (ICD) from LUH (ICD-9 codes 410.*, 411.*, 412.*, 414.* or ICD-10 codes I20.0, I21.*, I22.*, I23.*, I24.*, I25.*), or (ii) significant coronary artery disease (!50%) on coronary angiography, identified from a clinical registry of coronary angiography and percutaneous interventions at LUH between the years 1987 and 2012, or (iii) had undergone coronary artery bypass grafting at LUH between the years 2002 and 2011, or (iv) death from coronary artery disease or myocardial infarction in the Icelandic Registry for Causes of Death. Controls were participants in various genetic studies at deCODE Genetics without known cardiovascular disease.
Other biological traits. Association testing was performed for 2,491 binary and quantitative traits in our database, which has been described previously (10) . This database includes extensive medical information on a variety of diseases and traits that have been obtained in collaborations with medical specialists at LUH and other medical centers in Iceland. For this analysis, P < 6.7 Â 10 À6 was considered to be significant, accounting for the number of phenotypes tested for each of the three variants.
Genotyping and imputation
Whole-genome sequencing and imputation. Genotyping of all samples was carried out at deCODE Genetics in Reykjavik, Iceland, using methods previously described (10) . In brief, whole-genome sequencing was performed for 8,453 Icelanders who were recruited as part of various genetic programs at deCODE Genetics, to a mean depth of at least 10Â (median 32Â) using Illumina technology (Supplementary Material, Fig. S5 ). The sequencing was performed using the following three different library preparation methods and sequencing instruments from Illumina: (i) standard TruSeq DNA library preparation method; Illumina Figure S6 . SNPs and indels identified in the whole-genome sequencing data were identified using the Genome Analysis Toolkit HaplotypeCaller (GATK version 3.3.0) (26) and imputed into 150,656 Icelanders who had been genotyped with various Illumina SNP chips and their genotypes phased using long-range phasing (27, 28) . In addition, using the Icelandic genealogical database, genotype probabilities were calculated for first-and second-degree relatives of chipgenotyped individuals (29) . 30.5 million variants with imputation information over 0.80 were tested in the genome-wide scan of haptoglobin levels. The effects of sequence variants on proteincoding genes were annotated using the Variant Effect Predictor (VEP) (30) version 80. Single-track assay SNP genotyping. Single-SNP genotyping of the splice donor mutation in 4,955 Dutch subjects from the Nijmegen Biomedical Study (11) was carried out using the Centaurus (Nanogen) platform. Direct genotyping in Icelandic samples (6 imputed heterozygotes and 90 imputed non-carriers) revealed perfect concordance between the imputed genotypes and those obtained with single-SNP genotyping of the splice donor mutation (r 2 ¼ 1.00).
HP CNV genotyping. To genotype the HP CNV, we used an algorithm based on depth of coverage in whole-genome sequence data from 1,878 Icelanders. Sequencing coverage was calculated in bins of 1,000 bases, normalized and GC%-corrected per sample. All samples were analysed together and a scaled Poisson model was fitted to the data in each 1 kb bin. The model had a location and a scaling parameter, but assumed a linear relationship between mean and copy number. A Hidden Markov model was run where a sample could transit between copy number states between bins. The most probable path was used to discover CNVs and for each CNV, the copy number likelihood was calculated for each sample. The copy number likelihoods gave genotype likelihoods that were then phased and imputed into 150,656 chip-genotyped individuals and their close relatives. Supplementary Material, Figure S7 shows the clustering within a 1 kb bin within HP2, showing a trimodal distribution corresponding to three HP CNV genotypes.
Genotyping 'fast' (F) and 'slow' (S) subtypes of the HP CNV. We determined the HP CNV F-S subtype of each sample taking the copy-number of the CNV as given (see HP CNV genotyping) and by counting read pairs of four different types. In all of these four types of read pairs (1F and 1S for HP1, and 2FS and 2SS for HP2), the forward read aligns to a region overlapping exon 4 or 6 of HP and the reverse read aligns to a region between exon 4 and 5 or between exon 6 and 7. These regions are homologous between the copies of the CNV in the reference genome but differ at a small number of positions. The regions of the reverse read additionally differ from HPR by at least one base pair. In addition, the distance between the regions matches the insert size distribution of the sequencing data. Specifically, we incremented read counters {r 1 , r 2 , r 3 , r 4 } if read pair mapped to hg38 reference genome as follows: In addition, we required reverse reads to have a C at position chr16:72,057,703 for being counted as r 1 or r 3 and a T at position chr16:72,059,418 for being counted towards r 2 or r 4 . Furthermore, both ends of all read pairs had to pass quality filters, i.e. they had to have an average Phred-scaled base calling quality above 20, have at least 80 bp aligned to the reference, have an alignment score of at least 80% of read length, and not be marked as a duplicate, as a secondary alignment or as a supplementary alignment. Given the counts {r 1 , r 2 , r 3 , r 4 } and the HP CNV: HP1/HP1,HP2/HP1 or HP2/HP2, likelihoods were computed for all genotypes possible given the alleles F, S, FS, and SS. More specifically, we computed likelihoods of the genotypes F/F, F/S, and S/S for HP1 homozygotes, likelihoods of F/FS, F/SS, S/FS, and S/SS for HP1/HP2 heterozygotes, and likelihoods of FS/FS, FS/SS, and SS/SS for H2 homozygotes. All other genotype likelihoods were set to 10
À12
. The likelihood of genotype G was computed as
where P i ðGÞ is given in Supplementary Material, Table S15 with ¼ 10
À6
.
Association analyses
Generalized linear regression models were used to test for associations between sequence variants and quantitative traits, assuming an additive genetic model. Let y be the vector of quantitative measurements, and let g be the vector of expected allele counts for the SNP being tested. We assume the quantitative measurements follow a normal distribution with a mean that depends linearly on the expected allele at the variant and a variance covariance matrix proportional to the kinship matrix:
where
is the kinship matrix as estimated from the Icelandic genealogical database. Logistic regression was used to test for association between sequence variants and binary traits. Other available individual characteristics that correlate with disease status were also included in the model as nuisance variables. These characteristics were: sex, county of birth, current age or age at death (first-and second-order terms included), blood sample availability for the individual and an indicator function for the overlap of the lifetime of the individual with the timespan of phenotype collection. Testing was performed using the likelihood ratio statistic. Linkage disequilibrium (LD) score regression. To account for inflation in test statistics due to cryptic relatedness and stratification, we applied the method of LD score regression (31) . With a set of 1.1 million variants we regressed the v 2 statistics from our genome-wide scan against LD score and used the intercept as a correction factor. The LD scores were downloaded from an LD score database (see URLs). The estimated correction factors for the reported traits are given in Supplementary Material, Table S16 .
Significance thresholds for genome-wide significance. The threshold for genome-wide significance for the genome-wide scan for haptoglobin levels was corrected for multiple testing using a class-specific Bonferroni procedure based on the predicted functional impact of classes of variants (32) . This yielded significance thresholds of 1.9 Â 10 À6 for high-impact variants (including stopgained, frameshift, splice acceptor or donor, n ¼ 8,862), 1.1 Â 10
À7
for moderate-impact variants (including missense, splice-region variants and in-frame indels, n ¼ 153,198) and 5.5 Â 10 À10 for lowimpact variants (n ¼ 30,351,107).
Haplotype analysis. For haplotype analysis for quantitative traits, regression was done after centering the trait by subtracting its mean and fitting a model without an intercept term. We assumed the centered quantitative measurements follow a normal distribution with a mean l that depends linearly on the imputed genotype of haplotype h i for the three variants at the HP locus (i 2 0; 1; 2; 3 f ), i.e.
Note that P i h i ¼ 2 since the four haplotypes are the only ones observed in our data involving these three variants. Linear regression was then performed in the same way as for the sequence variants before, assuming the measurements having a variance covariance matrix proportional to the kinship matrix. In the logistic regression for binary traits, imputed genotypes of haplotypes where used assuming an additive model as for the quantitative traits and the risk was calculated relative to the average population.
Heritability
We estimated the heritability of haptoglobin levels based on the phenotypic correlation between 1,705 full siblings. Assuming only additive gene action, the full sibling phenotypic variance is equal to the sum of half the additive genetic variance plus environmental variance. Twice the full sibling phenotypic correlation is therefore an upper bound for heritability. Phenotypic correlation was assessed using Spearman's rank correlation and a 95% confidence interval was estimated by bootstrap sampling.
Fraction of variance explained
The fraction of the phenotypic variance in haptoglobin levels explained by the intentified variants was calculated using the formula 2f 1 À f ð Þa 2 in which f denotes the minor allele frequency and a is the adjusted additive effect in s.d.
RNA sequencing
Preparation of Poly-A cDNA sequencing libraries. The quality and quantity of isolated total RNA samples were assessed using the Total RNA 6000 Nano chip for the Agilent 2100 Bioanalyzer. cDNA libraries derived from Poly-A mRNA were generated using Illumina's TruSeq RNA Sample Prep Kit. Briefly, Poly-A mRNA was isolated from total RNA samples (1-4 lg input) using hybridization to Poly-T beads. The Poly-A mRNA was fragmented at 94 C, and first-strand cDNA was prepared using random hexamers and the SuperScript II reverse transcriptase (Invitrogen). Following second-strand cDNA synthesis, end repair, addition of a single A base, adaptor ligation, AMPure bead purification, and PCR amplification, the resulting cDNA was measured on a Bioanalyzer using the DNA 1000 Lab Chip. Sequencing. Samples were clustered on to flowcells using Illumina's cBot and the TruSeq PE cluster kits v2. Paired-end sequencing was performed with either GAIIx instruments using the TruSeq SBS kits v5 from Illumina or HiSeq 2000 instruments using TruSeq v3 flowcells/SBS kits; read lengths were 2 Â 76, 2 Â 101 or 2 Â 125 cycles.
Read alignment. RNA sequencing reads were aligned to Homo sapiens Build 38 with TopHat (33) version 2.0.12 with a supplied set of known transcripts in GTF format (RefSeq hg38; Homo sapiens, NCBI, build 38). TopHat was configured such that it attempts first to align reads to the provided transcriptome then, for reads that do not map fully to the transcriptome, it attempts to map them onto the genome. Because of the homology of the HP gene to itself (due to the common HP CNV) and the neighboring gene HPR, we extracted unmapped reads and reads aligning to the region chr16:72,054,592-72,077,246 (hg38), encompassing only the two genes HP and HPR, filtered low quality reads with Sickle (34) (version 1.33), and re-aligned them using the Burrows-Wheeler Aligner (BWA-MEM 0.7.10), with minimum alignment score 50, to five transcripts for the two genes (HP; HP1F: NM_001126102.2: r.256G > A, r.268C > T, r.269A > G, r.272G > A; HP1S: NM_001126102.2; HP2FS: NM_005143.4; HP2SS: NM_005143.4: r.256A > G, r.268T > C, r.269G > A, r.272A > G; HPR: NM_020995.3). Ambiguous alignments were resolved based on alignment score and, in the event of equal scores, the fragment with length closest to the median fragment length in the experiment was chosen. Fragment length distribution was evaluated separately for each individual sample using 10 million fragments that in the TopHat alignment aligned to exons larger than 500bp. If the alignment score and fragment length did not resolve ambiguity, the alignment group was labeled as such for downstream processing.
Probabilistic assignment of ambiguously aligned fragments. Due to the copy number variation, homology in the region and 'fast' and 'slow' transcripts variations, ambiguous alignments needed to be assigned to the five transcripts HP1F, HP1S, HP2FS, HP2SS and NM_020995 probabilistically for each individual. These probabilities were based on estimation of relative abundance: (i) the relative total expression for HP and HPR as estimated by the ratio median coverage per base for the last exons of HP and HPR (the last exon of HPR does not have homology with the rest of HPR or HP); (ii) the relative abundance of the HP transcripts with the HP2 allele (HP2FS or HP2SS) versus HP1 allele (HP1F or HP1S) was evaluated based on the number of fragments covering the splice junction between exons 4 to 5 in HP2FS/SS (a sequence unique to the HP2 allele) divided by total expression as estimated by the median coverage per base of the last exon in HP that is common to all HP transcripts but does not otherwise have homology with the rest of the HP gene; (iii) relative abundance of the 'fast' and 'slow' alternatives of the HP1 allele (HP1F versus HP1S) and HP2 allele (HP2FS versus HP2SS) was evaluated based on fragments depth at bases 256, 268, 269 and 272 in 'fast' and 'slow' variations of the HP transcripts. Incrementally, (i), (ii) and (iii) provide estimates of relative expression of the five transcripts as fractions that we assign as probabilities for fragments that map equally well to more than one of the transcripts.
Expression estimation. For each individual, the fragment counts at a base position b in a transcript t was estimated as N t bÞ ¼ P f p t ðf Þ, where N t ðbÞ is the number of mapped fragments covering position b in transcript t, calculated as the sum over all (ambiguous) fragments f covering the position where p t ðf Þ is the estimated probability that fragment f originates from transcript t. Fragment counts were then normalized by total sequencing depth using a number of mapped reads M from the transcriptome-wide TopHat alignment calculated using the CollectRnaSeqMetrics tool in Picard version 1. Expression association and estimation of haplotypic effects. To model RNA expression, we employed a generalized linear model (GLM) assuming expression levels to follow a gamma distribution with mean l > 0 and a dispersion parameter u > 0. The mean was assumed to be of the linear form with additive genetic effects:
where g i are imputed genotypes, 0 g i 2, and a is an intercept term; the covariate terms were age when the sample was taken, gender, sequencing read length and exonic rate (all standardized to have mean zero and variance 1). This model is suitable for capturing the skewness of the expression data, nonnegativity of the expression values and the variance increasing with higher mean (see Fig. 3 ). Maximum likelihood was used for parameter estimation and statistical inference was based on the asymptotic chi-square distribution of the likelihood ratio test statistic. For testing of association of the three variants HP CNV, splice donor mutation and rs35283911 with RNA expression, the g i s in the model corresponded to the imputed genotypes of the variants and no constraints were made for the intercept a and the b i s. In the case of estimating haplotypic effects, no intercept term was used (a ¼ 0) and g i corresponded to the imputed genotype of haplotype h i for the three variants at the HP locus (i2 0; 1; 2; 3 f ). Note that P i g i ¼ 2 since the four haplotypes are the only ones observed in our data involving these three variants. This model allows one to interpret the parameter b i as the absolute RNA expression level for haplotype h i . We therefore made the restriction b i ! 0 based on the natural assumption that RNA expression cannot be negative.
Allele-specific expression analysis. One of the splice donor mutation carriers in the RNA sequencing dataset was also heterozygous for the synonymous variant rs5475-A in HP (allele frequency ¼ 7.8%), where the G allele of rs5475 was on the same chromosome as the splice donor mutation. In RNA sequencing reads covering the position of rs5475, only the A allele was observed (eight reads in total); thus, no read originating from the chromosome carrying the splice donor mutation was observed. To estimate the significance of this observation, we looked at other heterozygous carriers of rs5475. Among the splice donor mutation non-carriers in the RNA sequencing data, there were 153 heterozygous carriers of rs5475 (median read coverage of 26 at the position of the variant). Assuming the count of reads with alternative alleles out of n reads to follow a binomial distribution B(n,p) with the same proportion parameter p (of alternative alleles) for all rs5475 heterozygotes not carrying the splice donor mutation, we estimated p to be 0.49 (95% CI 0.48-0.51; N alternative bases ¼ 2,629, N total bases ¼ 5,333) using maximum likelihood; this indicates a very little mapping bias at the position of the variant rs5475 due to alignment to a reference transcriptome. Now, returning to the splice donor mutation carrier, the null hypothesis 'number of reads having the alternative follows B(n,p) with P ¼ 0.49' is rejected at a P ¼ 0.0079; the 95% confidence interval for the proportion parameter (of alternative alleles) for the splice donor carrier is (0.63,1) assuming a binomial model.
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